N-(4-氨基丁基)-5-氯萘-2-磺酰胺盐酸盐 | 88519-57-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: N-(4-氨基丁基)-5-氯萘-2-磺酰胺盐酸盐
• 中文别名: N-(4-氨基丁基)-5-氯-2-萘磺酰胺盐酸盐
• 英文名称: W-13
• 英文别名: W-13 hydrochloride；N-(-4-aminobutyl)-5-chloro-2-naphthalenesulfonamide hydrochloride；N-(4-Aminobutyl)-5-chloronaphthalene-2-sulfonamide Hydrochloride；N-(4-aminobutyl)-5-chloronaphthalene-2-sulfonamide;hydrochloride
• CAS: 88519-57-7
• 化学式: C₁₄H₁₇ClN₂O₂S*ClH
• mdl: MFCD00058030
• 分子量: 349.281
• InChiKey: QKAALLVQBOLELJ-UHFFFAOYSA-N

物化性质

• 熔点：
  241-243°C
• 溶解度：
  H2O：推荐使用 5 mM 的储备液。这些库存在 4°C 下可稳定保存长达 6 个月。可溶

计算性质

• 辛醇/水分配系数(LogP)：
  1.73
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  80.6
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2935009090
• 安全说明：
  S22,S24/25

文献信息

• Dopamine analog amide
  申请人：——

  公开号：US20010056116A1

  公开（公告）日：2001-12-27

  The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug. In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be ingested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.

  该发明涉及使用脂肪酸载体和神经活性药物形成前药。该前药在胃和血液流动环境中稳定，并可通过口服递送。该前药容易穿过血脑屏障。一旦进入中枢神经系统，前药被水解成脂肪酸载体和药物以释放药物。在首选实施方式中，载体是4,7,10,13,16,19二十二碳六烯酸，药物是多巴胺。两者都是中枢神经系统的正常成分。药物和载体之间的共价键通常是酰胺键，这种键可以在胃的条件下存活。因此，前药可以被摄入，并且不会在胃中完全水解成载体分子和药物分子。
• Use of a modulator of protein phosphorylation in the treatment of amyloidosis associated with Alzheimer's disease
  申请人：THE ROCKEFELLER UNIVERSITY

  公开号：EP0457295A2

  公开（公告）日：1991-11-21

  Disclosed is the use of at lease one kinase modulator or phosphatase modulator being capable of increasing or decreasing the rate of proteolytic processing of proteins found in intracellular neurofibrillary tangles and extracellular amyloid plaques for the preparation of a pharmaceutical composition for the treatment of amyloidosis associated with Alzheimer's disease, wherein said pharmaceutical composition contains said modulator in an amount effectively regulating phosphorylation of said proteins.

  公开了至少一种激酶调节剂或磷酸酶调节剂的用途，它们能够提高或降低细胞内神经纤维缠结和细胞外淀粉样斑块中蛋白质的蛋白水解处理速度，用于制备治疗与阿尔茨海默病相关的淀粉样变性的药物组合物，其中所述药物组合物含有所述调节剂，其用量可有效调节所述蛋白质的磷酸化。
• Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
  申请人：Massachusetts Institute of Technology

  公开号：US20020052407A1

  公开（公告）日：2002-05-02

  It has been discovered that the stimulation of &bgr;-adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising &bgr;-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by &bgr;-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E 2 (PG E 2 ), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of &bgr;-adrenergic receptors. It has further been found that the increase in APP synthesis caused by 8Br-cAMP, PG E 2 , or forskolin is inhibited by immunosuppressants, immunophilin ligands, or anti-inflammatory agents, such as cyclosporin A, and FK-506 (tacrolimus), as well as ion-channel modulators, including ion chelating agents such as EGTA, or calcium/calmodulin kinase inhibitors, such as KN93. The present invention has broad implications in the alleviation, treatment, or prevention of neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.

  研究发现，刺激肾上腺素能受体会激活 cAMP 的形成，从而导致星形胶质细胞中 APP 和 GFAP 的合成增加。因此，在体外或体内将神经元细胞暴露于某些由肾上腺素能受体配体或激动剂（包括去甲肾上腺素、异丙肾上腺素等）组成的组合物中，会增加 APP mRNA 的转录，从而导致 APP 的过量产生。肾上腺素能受体拮抗剂（如普萘洛尔）可阻止这些增加。用 8Br-cAMP、前列腺素 E 2 (PG E 2 ) 、福斯可林和酒石酸烟碱也会增加 APP 的合成，包括 mRNA 和全蛋白水平的增加，以及胶质纤维酸性蛋白（GFAP）表达的增加。本研究公开了通过 cAMP 信号转导或激活肾上腺素能受体调节 APP 过度表达和介导反应性星形胶质细胞增多的组合物和方法。研究进一步发现，8Br-cAMP、PG E 2 和 FK-506 （他克莫司），以及离子通道调节剂，包括离子螯合剂（如 EGTA）或钙/钙调蛋白激酶抑制剂（如 KN93）。本发明在缓解、治疗或预防神经系统疾病和神经退行性疾病（包括阿尔茨海默病）方面具有广泛的意义。
• COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS AND NEURODEGENERATIVE DISEASES
  申请人：Massachusetts Institute of Technology Inc.

  公开号：EP1242063A1

  公开（公告）日：2002-09-25
• TREATMENT OF FIBROTIC EYE DISORDERS
  申请人：University of East Anglia

  公开号：EP2323637A1

  公开（公告）日：2011-05-25